Ir al contenido
Georgia Commons

Asamblea General de Georgia · Texto completo

HB 473: Controlled substances; Schedule I; provide certain provisions

Versión Enrolled, la más reciente que tiene LegiScan · Última acción: 1 de mayo de 2025 · Passed

El texto tal como lo tiene LegiScan, leído del PDF que publica la legislatura, sin los números de línea del margen, los encabezados ni los pies de página. Aquí los saltos de línea se unen en párrafos; no se cambia ninguna palabra. El texto está en inglés.

Las palabras subrayadas son las que el proyecto de ley agrega a la ley vigente y las tachadas son las que elimina, tal como las muestra el proyecto impreso.

Copiar para un LLM, Ver en Markdown y Enviar a una IA usan la versión Markdown: este texto, seguido de los resúmenes bajo un encabezado que los identifica como nuestros. Ver texto sin formato es el texto solo.

Volver al resumen

House Bill 473 (AS PASSED HOUSE AND SENATE)

By: Representatives Stephens of the 164th, Hawkins of the 27th, and Newton of the 127th

A BILL TO BE ENTITLED

AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to provide for certain provisions relating to Schedule I controlled substances; to provide for certain provisions relating to the definition of dangerous drugs; to provide for related matters; to provide for an effective date; to repeal conflicting laws; and for other purposes.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.

Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (TT) of paragraph (1) as follows: "(TT) Methyl 2-methyl-AP-237;"

SECTION 2.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (CC) of paragraph (3) as follows: "(CC) Acetylpsilocin (4-acetoxy-N,N-dimethyltryptamine, 4-AcO-DMT); Reserved;"

SECTION 3.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by adding a new subparagraph to paragraph (4) to read as follows: "(A.5) Ethylphenidate;"

SECTION 4.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by adding a new subdivision to division (13)(E)(ii) to read as follows: "(III) Tetrahydrothiophene group;"

SECTION 5.

Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding new paragraphs to subsection (b) to read as follows: "(12.8) Acoramidis;" "(17.07) Afamitresgene autoleucel;" "(62.45) Aprocitentan;" "(63.3) Arimoclomol;" "(68.133) Atidarsagene autotemcel;" "(69.23) Axatilimab-csfr;" "(153.65) Ceftobiprole medocaril sodium;" "(206.6) Coagulation Factor IX (recombinant);" "(213.2) Concizumab-mtci;" "(216.5) Cosibelimab-ipdl;" "(217.3) Crinecerfont;" "(220.5) Crovalimab-akkz;" "(238.5) Danicopan;" "(256.58) Deuruxolitinib;" "(256.8) Deutivacaftor;" "(316.45) Donanemab-azbt;" "(331.0504) Eladocagene exuparvovec-tneq; (331.0506) Elafibranor;" "(331.0515) Elaparvovec-dzkt;" "(332.3) Enmetazobactam;" "(332.73) Ensartinib; (332.75) Ensifentrine;" "(380.45) Exagamglogene autotemcel;" "(402.3) Flurpiridaz F 18;" "(415.005) Givinostat;" "(464.9) Imetelstat;" "(466.8) Immune globulin, Human;" "(469.02) Inavolisib;" "(487.09) Iomeprol;" "(512.1) Landiolol;" "(513.03) Lazertinib; (513.07) Lebrikizumab-lbkz;" "(513.79) LetibotulinumtoxinA-wlbg;" "(514.3) Levacetylleucine;" "(520.1) Lifileucel;" "(530.3) Lovotibeglogene autotemcel;" "(540.47) Marstacimab-hncq;" "(540.8) Mavorixafor;" "(638.9) Nemolizumab-ilto;" "(649) Nogapendekin alfa inbakicept-pmln;" "(661.02) Obecabtagene autoleucel;" "(663.03) Olezarsen;" "(681.55) Palopegteriparatide;" "(692.5175) Pegulicianine;" "(835.7) Resmetirom;" "(836.75) Revumenib;" "(852.55) Seladelpar;" "(860.5) Smallpox and mpox (vaccinia) vaccine;" "(881.04) Sofpironium;" "(883.55) Sotatercept-csrk;" "(927.3) Sulopenem etzadroxil;" "(931.17) Tarlatamab-dlle;" "(967.625) Tislelizumab-jsgr;" "(973.55) Tovorafenib;" "(1021.65) Vadadustat;" "(1025.3) Vanzacaftor;" "(1037.4) Vorasidenib;" "(1039.05) Xanomeline;" "(1042.035) Zanidatamab-hrii;" "(1042.047) Zenocutuzumab-zbco;" "(1042.79) Zolbetuximab-clzb;"

SECTION 6.

Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding a new subparagraph to paragraph (59) of subsection (b) to read as follows: "(ZZ.5) Peanut (arachis hypogaea) allergen powder-dnfp;"

SECTION 7.

This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval.

SECTION 8.

All laws and parts of laws in conflict with this Act are repealed.